EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Design, synthesis, in vitro evaluation, and molecular modeling studies of N ‐substituted benzomorphans, analogs of LP2 , as novel MOR ligands

Giuliana Costanzo, Vincenzo Patamia, Rita Turnaturi, Carmela Parenti, Chiara Zagni, Jessica Lombino, Emanuele Amata, Agostino Marrazzo, Lorella Pasquinucci, Antonio Rescifina iD

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14220 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2023. Written by Giuliana Costanzo and 9 co-authors. Institution: Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. Major MEDLINE topics: Receptors, Opioid, mu, Receptors, Opioid, delta. Cited 7 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Università di Catania.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

6,7‐Benzomorphans have been investigated in medicinal chemistry for developing new drugs. This nucleus could be considered a versatile scaffold. The physicochemical properties of benzomorphan N ‐substituent are crucial in achieving a definite pharmacological profile at opioid receptors. Thus, the dual‐target MOR/DOR ligands LP1 and LP2 were obtained through N ‐substituent modifications. Specifically, LP2, bearing as N ‐substituent the (2 R / S )‐2‐methoxy‐2‐ phenylethyl group, is a dual‐target MOR/DOR agonist and is successful in animal models of inflammatory and neuropathic pain. To obtain new opioid ligands, we focused on the design and synthesis of LP2 analogs. First, the 2‐methoxyl group of LP2 was replaced by an ester or acid functional group. Then, spacers of different lengths were introduced at N ‐substituent. In‐vitro, their affinity profile versus opioid receptors has been performed through competition binding assays. Molecular modeling studies were conducted to deeply analyze the binding mode and the interactions between the new ligands and all opioid receptors.

Subjects

MeSH terms (MEDLINE)

Receptors, Opioid, muReceptors, Opioid, deltaAnimalsBenzomorphansLigandsReceptors, OpioidStructure-Activity Relationship

Author keywords

6,7-benzomorphandocking studiesopioid receptorradioligand competition-binding

Substances

Receptors, Opioid, muReceptors, Opioid, deltaBenzomorphansLigandsReceptors, Opioid

Authors and institutions

  • Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
  • Department of Drug and Health Sciences, University of Catania, Catania, Italy.

ORCID profiles: Antonio Rescifina

Funding

  • Università di Catania

Cite

APA

Costanzo, G., Patamia, V., Turnaturi, R., Parenti, C., Zagni, C., Lombino, J., Amata, E., Marrazzo, A., Pasquinucci, L., & Rescifina, A. (2023). Design, synthesis, in vitro evaluation, and molecular modeling studies of N ‐substituted benzomorphans, analogs of LP2 , as novel MOR ligands. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14220

Vancouver

Costanzo G, Patamia V, Turnaturi R, Parenti C, Zagni C, Lombino J, et al. Design, synthesis, in vitro evaluation, and molecular modeling studies of N ‐substituted benzomorphans, analogs of LP2 , as novel MOR ligands. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14220

BibTeX
@article{Costanzo2023,
  author = {Costanzo, Giuliana and Patamia, Vincenzo and Turnaturi, Rita and Parenti, Carmela and Zagni, Chiara and Lombino, Jessica and Amata, Emanuele and Marrazzo, Agostino and Pasquinucci, Lorella and Rescifina, Antonio},
  title = {Design, synthesis, in vitro evaluation, and molecular modeling studies of N ‐substituted benzomorphans, analogs of LP2 , as novel MOR ligands},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14220}
}
Start for free →